Filing Flows

Filing Flows › Companies › Monte Rosa Therapeutics › Cash flow

Monte Rosa Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$42.5M in Q3 2026 · −$174M over twelve months

Operating cash flow−$41.0M
Capital spending−$1.6M
Free cash flow−$42.5M
Cash / net income-13.4×

Analysis

In Q3 2026, Monte Rosa Therapeutics generated −$41.0M of operating cash flow and spent $1.6M on capital projects, leaving free cash flow of −$42.5M. That is $142M less than in Q3 2025 ($99.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$165M; the largest uses were other investing ($351M), operating cash flow ($165M), capital spending ($8.9M); besides operations, cash came from other financing ($349M), shares issued ($13.1M); the cash balance fell by $163M.

Operating cash flow was −$41.0M against net income of $3.1M — -13.4× profit, less cash than reported earnings, worth checking against working capital. The largest differences: accrued liabilities +$8.0M, stock-based pay +$6.3M, deferred revenue −$4.4M.

Free cash flow

Monte Rosa Therapeutics: free cash flow by quarterMonte Rosa Therapeutics: free cash flow by quarter$129MQ4 2024−$47.1MQ1 2025−$36.4MQ2 2025$99.8MQ3 2025−$43.8MQ4 2025−$39.2MQ1 2026−$48.8MQ2 2026−$42.5MQ3 2026
Operating cash flow less capital spending.
Monte Rosa Therapeutics: operating cash flow against capital spendingMonte Rosa Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending$129M$183KQ4 2024−$45.5M$1.6MQ1 2025−$34.7M$1.7MQ2 2025$100M$651KQ3 2025−$43.0M$767KQ4 2025−$37.4M$1.9MQ1 2026−$44.1M$4.7MQ2 2026−$41.0M$1.6MQ3 2026
Latest (Q3 2026): Operating cash flow −$41.0M, Capital spending $1.6M.

Capital allocation, year by year

Monte Rosa Therapeutics: where the cash came from (up) and went (down), by fiscal yearMonte Rosa Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$59.4MFY2021: Shares issued $143MFY2021: Asset sales $79KFY2021: Capital spending −$9.7M$143MFY2021FY2022: Operating cash flow −$92.5MFY2022: Shares issued $20.5MFY2022: Asset sales $109KFY2022: Capital spending −$12.9M$20.6MFY2022FY2023: Operating cash flow −$43.8MFY2023: Shares issued $2.0MFY2023: Asset sales $62KFY2023: Capital spending −$19.0M$2.1MFY2023FY2024: Operating cash flow $42.0MFY2024: Shares issued $1.1MFY2024: Capital spending −$4.0M$43.1MFY2024FY2025: Operating cash flow −$22.8MFY2025: Shares issued $345MFY2025: Capital spending −$4.7M$345MFY2025
Over these 5 years operating cash flow totalled −$176M; the largest uses were operating cash flow ($218M) and capital spending ($50.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$45.2M
Debtnone
Net cash$45.2M
Cash runway3 months

Monte Rosa Therapeutics is burning cash: its operations consume cash, a free cash flow of −$174M a year at the current rate against $45.2M of cash and investments: a runway of about 3 months before any new financing.

Where the cash came from and went

Monte Rosa Therapeutics: sources (+) and uses (−) of cash, Q3 2026Monte Rosa Therapeutics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$44.9MOperating cash flow−$41.0MOther investing−$3.0MCapital spending−$1.6MShares issued$568K
Monte Rosa Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Monte Rosa Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Other investing−$351MOther financing$349MOperating cash flow−$165MCash drawn (+) / kept (−)$163MShares issued$13.1MCapital spending−$8.9M

From profit to cash

Monte Rosa Therapeutics: net income to operating cash flow, Q3 2026Monte Rosa Therapeutics: net income to operating cash flow, Q3 2026Net income$3.1MDepreciation & amortization$2.9MStock-based pay$6.3MPayables−$3.4MAccrued liabilities$8.0MDeferred revenue−$4.4MPrepaid and other assets$728KOperating cash flow−$41.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$41.0M−$1.6M$568K$44.9M−$42.5M
Q2 2026−$44.1M−$4.7M$2.6M$69.8M−$48.8M
Q1 2026−$37.4M−$1.9M$4.5M−$30.0M−$39.2M
Q4 2025−$43.0M−$767K$5.4M$78.5M−$43.8M
Q3 2025$100M−$651K$348K−$139M$99.8M
Q2 2025−$34.7M−$1.7M—$9.0M−$36.4M
Q1 2025−$45.5M−$1.6M$14K$146M−$47.1M
Q4 2024$129M−$183K$379K−$98.6M$129M

Monte Rosa Therapeutics: income statement and cash flow

Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%. The chart follows the revenue to costs, profit and cash.

Monte Rosa Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.